

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/249299 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/030993

(22) International Filing Date:
24 May 2024 (24.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/469,283 26 May 2023 (26.05.2023) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063
(US).

(72) Inventors: **KNOX, John E.**; Revolution Medicines, Inc.,
700 Saginaw Drive, Redwood City, CA 94063 (US).
KOLTUN, Elena S.; Revolution Medicines, Inc., 700 Sag-
inaw Drive, Redwood City, CA 94063 (US). **PARSONS,**
Dylan E.; Revolution Medicines, Inc., 700 Saginaw Drive,
Redwood City, CA 94063 (US). **TOMLINSON, Aidan**;
Revolution Medicines, Inc., 700 Saginaw Drive, Redwood
City, CA 94063 (US). **BURNETT, G. Leslie**; Revolution
Medicines, Inc., 700 Saginaw Drive, Redwood City, CA
94063 (US). **CREGG, James**; Revolution Medicines, Inc.,
700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL,**
Adrian L.; Revolution Medicines, Inc., 700 Saginaw Drive,
Redwood City, CA 94063 (US). **BUCKL, Andreas**; Revo-
lution Medicines, Inc., 700 Saginaw Drive, Redwood City,
CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael J.** et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

WO 2024/249299 A2

(54) Title: RAS INHIBITORS

(57) Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.